Can Diet Help Non-Obese Individuals with Non-Alcoholic Fatty Liver Disease (NAFLD)? by Merchant, Hamid A.
University of Huddersfield Repository
Merchant, Hamid A.
Can Diet Help Non­Obese Individuals with Non­Alcoholic Fatty Liver Disease (NAFLD)?
Original Citation
Merchant, Hamid A. (2017) Can Diet Help Non­Obese Individuals with Non­Alcoholic Fatty Liver 
Disease (NAFLD)? Journal of Clinical Medicine, 6 (9). ISSN 2077­0383 
This version is available at http://eprints.hud.ac.uk/id/eprint/33480/
The University Repository is a digital collection of the research output of the
University, available on Open Access. Copyright and Moral Rights for the items
on this site are retained by the individual author and/or other copyright owners.
Users may access full items free of charge; copies of full text items generally
can be reproduced, displayed or performed and given to third parties in any
format or medium for personal research or study, educational or not­for­profit
purposes without prior permission or charge, provided:
• The authors, title and full bibliographic details is credited in any copy;
• A hyperlink and/or URL is included for the original metadata page; and
• The content is not changed in any way.
For more information, including our policy and submission procedure, please
contact the Repository Team at: E.mailbox@hud.ac.uk.
http://eprints.hud.ac.uk/
Journal of
Clinical Medicine
Case Report
Can Diet Help Non-Obese Individuals with
Non-Alcoholic Fatty Liver Disease (NAFLD)?
Hamid A. Merchant ID
Department of Pharmacy, School of Applied Sciences, University of Huddersfield, Queensgate, Huddersfield
HD1 3DH, UK; hamid.merchant@hud.ac.uk; Tel.: +44-(0)-1484-472387; Fax: +44-(0)-1484-472182
Academic Editor: Paul Huang
Received: 14 August 2017; Accepted: 13 September 2017; Published: 19 September 2017
Abstract: Subjects diagnosed with non-alcoholic fatty liver disease (NAFLD) or hepatic steatosis are
usually obese or overweight. NAFLD has also been reported in many non-obese healthy subjects as
an incidental finding during imaging. Subjects with early-stage NAFLD who are otherwise healthy
are often left unmanaged in current clinical practice; it is not clear if an early intervention in those
individuals would be of any benefit in preventing NAFLD progression to more serious conditions.
Since many of these subjects are non-alcoholic and have a normal body mass index (BMI), an intensive
lifestyle change program is not usually recommended. This report presents an otherwise healthy
non-alcoholic subject with incidental NAFLD having a normal BMI and a waist circumference below
90 cm who successfully reversed his condition by undertaking a lifestyle intervention. The case report
is expected to encourage large cohort studies to substantiate the benefits of dietary interventions in
alleviating hepatic steatosis among non-obese individuals.
Keywords: diabetes risk; insulin resistance; fatty liver disease; hyperinsulinemia; NAFLD; NASH;
intensive lifestyle change program
1. Introduction
Non-alcoholic fatty liver disease (NAFLD) or hepatic steatosis is usually common in subjects who
are obese or overweight. It is very common in non-obese South Asians with considerably lower body
mass index with manifestations of abdominal adiposity. Recently, these subjects are often categorized
as “lean NAFLD” [1] or “normal weight metabolically obese” [2]. NAFLD is very common and
estimates show that one in three individuals in UK may have some fatty deposits in the liver [3]. These
abnormal deposits of lipids within hepatic cells hampers homeostasis of triglyceride synthesis and
storage. NAFLD has been shown to be a major risk factor for diabetes and cardiovascular disease; the
soaring numbers of diabetes and cardiovascular events is already a major burden on national health
services. NAFLD may cause liver damage if left uncontrolled and may progress into steatohepatitis
(NASH) and even cirrhosis. The research has shown that dietary interventions have a close relationship
with metabolic diseases and may also benefit these patients. This report presents a case of an otherwise
healthy non-obese subject, recently diagnosed with an early stage NAFLD who undertook a low-carb
diet and was successful in reversing his condition. This is in support to the existing evidence in
scientific literature that dietary modulations can be very beneficial in treating NAFLD and reducing
the burden in hepatology, diabetes and cardiology.
2. Case Report
Here, we present a 35 year old male (Table 1) living in North England with a South Asian
background (Pakistan), with a family history of diabetes and hypertension, and a history of recurring
renal stones, recently diagnosed with high blood pressure on a 24 h ambulatory blood pressure
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(BP) monitoring (awake averages: 158/107 and during sleep: 123/83). The patient is otherwise
healthy, is not on any medication but takes occasional over-the-counter antihistamines for seasonal
hay fever, and has never smoked or consumed alcohol. This subject is a typical example of a “healthy”,
young South-Asian subject living in England. The subject has normal fasting glucose and HbA1C.
The two-hour post-oral glucose load (75 g) serum glucose level was also normal, but his serum
insulin level was significantly raised (354.4 pmol/L), suggesting a remarkable insulin resistance. This
surge in serum insulin also corresponded to the postprandial rise in blood pressure in this subject
studied at another occasion (11:00 am, Figure 1). The patient was found with elevated liver enzymes
during screening and, on further investigation, liver was found patchy in echo texture on ultrasound,
suggesting a non-alcoholic fatty liver disease (NAFLD). Other investigations including electrolytes,
C-reactive protein, fasting blood sugar, glycated haemoglobin, full blood count, thyroid-stimulating
hormone, autoantibodies, bone profile and urine protein, urine metadrenaline, and serum lipid profiles
were unremarkable.
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Figure  1.  Twenty‐four  hour  ambulatory  blood  pressure  measurement  in  the  subject.  The  lines 
represents systolic/diastolic blood pressure recorded over a 24 h period, where  the measurements 
during sleep shows a nighttime dipping (indicated by crossed‐marks). The inset shows a distribution 
of measurements  (filled  symbols) with minimum/maximum  (red bars) and average  readings  (red 
filled‐circles) in the same subject during sleep/awake cycles, where “Sys” and “Dia” refer to systolic 
and diastolic blood pressures, respectively. 
Following  the  reports  of  NAFLD  and  post‐glucose  load  hyperinsulinemia,  the  subject 
undertook  a  low‐carb  diet  program  [4–7]  that  included  no  added  sugar  on  foods  and  drinks, 
minimum  or  occasional  intake  of  starchy  carbohydrates,  having  grilled  food  instead  of  fried, 
changing to wholemeal, increasing overall fibre intake, avoiding animal/saturated fats and having 
Figure 1. Twenty-four hour ambulatory blo d pres ure measurement in the subject. The lines
represents systolic/ i l r recor e over a 24 h period, where the measurements
during sle p shows a nighttime dip ing (indicated by cros ed-marks). The inset shows a distribution
of easure ents fi ls) with minimum/maximum (red bars) and average readings
(red filled-circles) in the same subject during sleep/awak cycles, where “Sys” and “Dia” refer to
systolic and diast lic blood pressures, respectively.
Following the reports of NAFLD and post-glucose load hyperinsulinemia, the subject undertook a
low-carb diet program [4–7] that included no added sugar on foods and drinks, minimum or occasional
J. Clin. Med. 2017, 6, 88 3 of 5
intake of starchy carbohydrates, having grilled food instead of fried, changing to wholemeal, increasing
overall fibre intake, avoiding animal/saturated fats and having polyunsaturated fats, taking more fish
and egg into diet, and grazing nuts (mainly cashews, walnuts, pecans, and almonds) during work
hours to curb the urge to eat. The subject achieved a significant reduction in waist circumference
within weeks, possibly a good indication of losing abdominal fat. On annual review, his liver enzymes
and post-glucose load insulin levels were back to normal, and waist circumference, body weight,
and BMI were significantly reduced (Table 1), suggesting that the insulin resistance and fatty liver
were reversed. The subject lost over 13% of his weight (although not intended, as the patient was not
overweight), but this was not surprising and have already reported in various studies [4–7]. There was,
however, no significant change in blood pressure in this subject albeit prior reports of reduction in BP
with weight loss in non-obese Asians, such as Japanese [8]. Although baseline lipid profile was normal,
there was a further reduction observed in triglycerides, non-HDL cholesterol, cholesterol/HDL ratio,
and an increase in serum HDL on annual review (Table 1).
Table 1. Subject characteristics at baseline and after lifestyle interventions.
Description Baseline Annual Review
Age (year) 35 36
Body weight (Kg) 59 51
Height (cm) 163 ~
BMI (Kg/m3) 22.3 19.1
Waist circumference (inches) 34 29
Fasting glucose (mmol/L) 4.6 –
HbA1c (mmol/mol) 37 33
Fasting glucose (2-h post glucose load), (mmol/L) 4.0 4.3
Insulin (2-h post glucose load), (pmol/L) 354.4 171.8
Total bilirubin (umol/L) 11 12
Alkaline phosphatase (iU/L) 130 97
ALT (iU/L) 75 17
Lipid profile
Serum cholesterol (mmol/L) 5.7 5.7
Serum triglycerides (mmol/L) 1.5 1.0
Serum HDL (mmol/L) 1.3 1.6
Serum cholesterol/HDL ratio 4.4 3.6
Serum LDL (mmol/L) 3.7 3.6
Non-HDL cholesterol (mmol/L) 4.4 4.1
Note: ~unchanged; – not tested.
3. Discussion
It is evidenced from the literature that many South Asians, even at a young age, with hypertension
and a family history of diabetes have a significantly high risk of developing diabetes [9]. It has been
reported that a significant population with relatively lower BMI and waist circumference, similar to
this subject, have a substantial risk of developing diabetes [1]. In addition to have a lower BMI, it is not
very common to have a substantially high waist circumference (the usual cut-off of >35 inch or 90 cm).
In a prospective epidemiological study, 75% of non-obese Bengali Indians with NAFLD were found to
have a BMI <25 kg/m2 [10]. It is, therefore, expected that many South Asians having undiagnosed early
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stages of NAFLD have a potentially higher risk of developing diabetes or progressing towards NASH
are unaware of the condition, so a major lifestyle intervention will not be encouraged, which may
otherwise prove useful for this population at this stage.
Zelber-Sagi et al. have reviewed the effects of various dietary interventions on hepatic
fat, including various types of fats and the association between added sugar in everyday foods,
fast-food-rich Western dietary patterns, and NAFLD [11]. Unwin have also criticised the current
guidelines of encouraging over-utilisation of complex carbohydrates, such as starchy foods, which
may potentially have a higher glycaemic index than the table sugar [4]. In his low-carb trial on 19
type 2 or pre-diabetes patients, a 9% reduction in body weight was found with an average of 15 cm
reduction in waist circumference. His patients also benefited with an improvement in their blood
pressures (systolic 148 ± 17 to 133 ± 15 mmHg, p < 0.005; diastolic 91 ± 8 to 83 ± 11 mmHg, p < 0.05)
and a reduction in serum gamma-GT (75.2 ± 54.7 to 40.6 ± 29.2 U/L) and serum cholesterol (5.5 ± 1.0
to 4.7 ± 1.2 mmol/L, p < 0.01). A 9% weight loss was also reported in a recent randomised controlled
trial on 227 overweight or obese adults with type 2 diabetes undertaking a low-carbohydrate diet
compared to only 2.5% with control; the glycaemic control was also improved in subjects on a low-carb
diet [5]. In another randomised weight intervention trial, Mayer et al. reported that weight loss among
subjects undertaking either a low-carb or a low-fat diet was similar, but those on a low-carb diet also
benefited from an improved glycaemic control and a significant antiglycemic drug dose reduction [7].
Similar reports of “deprescribing” antidiabetic medications have been reported in patients with type 2
diabetes undertaking intensive lifestyle change programs [12].
It has been reported that diets rich in fruits, vegetables, whole grains, dairy, and unsaturated fats
are associated with a lower prevalence of metabolic syndrome. Romero-Gómez in a recent review
have also suggested that lifestyle intervention and dietary modulations are useful across the wide
spectrum of NAFLD. The Mediterranean diet, characterized by low carbohydrates (sugars or refined
carbohydrates), and rich in monounsaturated/omega-3 fatty acids and antioxidants (polyphenols), has
been found useful in reducing liver fat to prevent the disease progression [6,13]. Giugliano and Esposito
have suggested that Mediterranean diet could also be beneficial in chronic inflammation associated
with visceral obesity, type 2 diabetes, and metabolic syndrome [14]. Recently, the Mediterranean diet
was also found superior to a low-fat diet in reducing intrapericardial-fat burden in a randomized
controlled trial [15], hinting their potential in preventing cardiovascular events.
4. Conclusions
NAFLD is common in non-obese South Asians with considerably lower BMI and waist
circumference without obvious manifestations of abdominal adiposity. Dietary interventions have
already proven beneficial in overweight or obese subjects with fatty liver. This study encourages that
dietary interventions can also be beneficial to individuals with fatty liver who are not yet overweight.
This, however, warrants large cohort studies to substantiate these findings.
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